Aeglea BioTherapeutics, Inc. (AGLE) At $10.09 Forms Top; 8 Bullish Analysts Covering Weyerhaeuser Company (WY)

Weyerhaeuser Company (NYSE:WY) Logo

Among 14 analysts covering Weyerhaeuser Company (NYSE:WY), 8 have Buy rating, 1 Sell and 5 Hold. Therefore 57% are positive. Weyerhaeuser Company had 36 analyst reports since September 11, 2015 according to SRatingsIntel. On Wednesday, June 29 the stock rating was upgraded by DA Davidson to “Buy”. The stock of Weyerhaeuser Company (NYSE:WY) has “Buy” rating given on Friday, October 6 by RBC Capital Markets. The company was maintained on Tuesday, March 15 by Argus Research. The firm earned “Outperform” rating on Friday, November 13 by Credit Agricole. The stock of Weyerhaeuser Company (NYSE:WY) earned “Neutral” rating by DA Davidson on Monday, May 9. The stock of Weyerhaeuser Company (NYSE:WY) earned “Hold” rating by BMO Capital Markets on Sunday, October 29. Citigroup maintained Weyerhaeuser Company (NYSE:WY) on Monday, April 30 with “Buy” rating. Dundee Securities downgraded the shares of WY in report on Friday, August 12 to “Neutral” rating. On Tuesday, September 15 the stock rating was upgraded by Bank of America to “Buy”. BMO Capital Markets downgraded Weyerhaeuser Company (NYSE:WY) on Monday, August 14 to “Market Perform” rating. See Weyerhaeuser Company (NYSE:WY) latest ratings:

30/04/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $41 New Target: $42 Maintain
24/01/2018 Broker: Bank of America Old Rating: Neutral New Rating: Buy Upgrade

Aeglea BioTherapeutics, Inc. (AGLE) formed multiple top with $11.00 target or 9.00% above today’s $10.09 share price. Aeglea BioTherapeutics, Inc. (AGLE) has $220.56 million valuation. The stock decreased 0.39% or $0.04 during the last trading session, reaching $10.09. About 221,891 shares traded. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) has risen 139.73% since June 14, 2017 and is uptrending. It has outperformed by 127.16% the S&P500. Some Historical AGLE News: ; 13/03/2018 – Aeglea BioTherapeutics 2017 Loss/Shr $1.80; 15/05/2018 – Dafna Capital Management LLC Exits Aeglea BioTherapeutics; 12/04/2018 – AEGLEA BIOTHERAPEUTICS PRESENTS NEW PHASE 1/2 TRIAL DATA DEMONSTRATING CLINICALLY RELEVANT TREATMENT EFFECTS IN ARGINASE 1 DEFICIENCY PATIENTS AT THE 2018 ACMG ANNUAL CLINICAL GENETICS MEETING; 05/04/2018 – Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AA; 12/04/2018 – Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Defi; 08/05/2018 – Aeglea BioTherapeutics 1Q Loss/Shr 49c; 03/04/2018 – AEGLEA BIOTHERAPEUTICS TO PRESENT NEW PHASE 1/2 TRIAL RESULTS IN ARGINASE 1 DEFICIENCY AT THE 2018 ACMG ANNUAL CLINICAL GENETICS MEETING; 26/03/2018 – Aeglea BioTherapeutics Appoints Dr. lvana Magovčević-Liebisch to Board of Directors; 02/04/2018 – Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials; 06/03/2018 – Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for lnherited Metabolic Disorders

Among 4 analysts covering Aeglea BioTherapeutics (NASDAQ:AGLE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeglea BioTherapeutics had 4 analyst reports since May 2, 2016 according to SRatingsIntel. The stock has “Buy” rating by Needham on Monday, May 9. BMO Capital Markets initiated Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) on Monday, May 2 with “Outperform” rating. Wells Fargo initiated Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) on Monday, May 2 with “Outperform” rating. As per Monday, May 2, the company rating was initiated by UBS.

Analysts await Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to report earnings on August, 8. They expect $-0.37 EPS, up 21.28% or $0.10 from last year’s $-0.47 per share. After $-0.49 actual EPS reported by Aeglea BioTherapeutics, Inc. for the previous quarter, Wall Street now forecasts -24.49% EPS growth.

Another recent and important Weyerhaeuser Company (NYSE:WY) news was published by which published an article titled: “New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus …” on June 12, 2018.

The stock decreased 3.05% or $1.17 during the last trading session, reaching $37.19. About 5.47M shares traded or 34.61% up from the average. Weyerhaeuser Company (NYSE:WY) has risen 11.40% since June 14, 2017 and is uptrending. It has underperformed by 1.17% the S&P500. Some Historical WY News: ; 27/04/2018 – Weyerhaeuser Sees 2Q Real Estate, Energy & Natural Resources Earnings Comparable to 1Q; 27/04/2018 – Weyerhaeuser 1Q Cash Flows From Operations $136; 22/04/2018 – DJ Weyerhaeuser Company, Inst Holders, 1Q 2018 (WY); 22/03/2018 – Weyerhaeuser Co. CDS Widens 8 Bps; 27/04/2018 – Weyerhaeuser 1Q Adj EPS 36c; 17/05/2018 – WEYERHAEUSER CO. DECLARES DIV ON SHRS; 25/04/2018 – Weyerhaeuser Co expected to post earnings of 33 cents a share – Earnings Preview; 22/05/2018 – Simons to represent Weyerhaeuser at Nareit REITweek: 2018 Investor Conference; 23/05/2018 – Columbia Bank Appoints Craig Eerkes as Chairman of Board to Succeed William Weyerhaeuser; 27/04/2018 – WEYERHAEUSER CO SAYS – CONTINUE TO EXPECT FY 18 ADJUSTED EBITDA FOR REAL ESTATE, ENERGY & NATURAL RESOURCES SEGMENT WILL BE APPROXIMATELY $250 MLN

Investors sentiment decreased to 0.94 in Q1 2018. Its down 0.20, from 1.14 in 2017Q4. It worsened, as 58 investors sold Weyerhaeuser Company shares while 284 reduced holdings. 67 funds opened positions while 256 raised stakes. 556.76 million shares or 2.10% more from 545.30 million shares in 2017Q4 were reported. Fort Washington Inv Advsr Oh invested 0.01% in Weyerhaeuser Company (NYSE:WY). 188,004 were reported by Granite Prns Ltd Liability Corp. 519,325 were reported by Stifel Fincl. Jpmorgan Chase & invested in 11.10 million shares. Leisure Mgmt holds 0.25% or 8,207 shares. Roberts Glore & Il invested 0.13% in Weyerhaeuser Company (NYSE:WY). Mariner Ltd Liability Corporation accumulated 0.01% or 7,219 shares. Weik Cap Mgmt reported 21,945 shares. Convergence Inv Ptnrs Ltd Liability invested in 0.01% or 2,178 shares. Axa invested 0% in Weyerhaeuser Company (NYSE:WY). Tompkins Fincl invested 0% in Weyerhaeuser Company (NYSE:WY). Marathon Asset Limited Liability Partnership reported 712,880 shares or 0.39% of all its holdings. Associated Banc holds 141,230 shares. Arrow Finance stated it has 1,335 shares or 0.01% of all its holdings. Amg Funds Ltd invested in 43,955 shares.

Weyerhaeuser Company (NYSE:WY) Institutional Positions Chart